pp-207 Cream

Indication: Erythromelalgia — rare painful peripheral vascular disorder causing severe burning pain in extremities Clinical stage: Phase 2 data positive; FDA-guided development into Phase 2/3 Modality: Small molecule (TRPV1 receptor antagonist) Mechanism / Target: Topical TRPV1 (transient receptor potential vanilloid type 1) receptor antagonist; blocks peripheral nociceptor heat-pain signalling at the site of erythromelalgia; topical delivery avoids systemic hyperthermia associated with oral TRPV1 blockers Route / form: Topical cream/gel (applied to affected extremities) Differentiation: First TRPV1 antagonist in development for erythromelalgia; topical formulation uniquely avoids systemic TRPV1 side effects (hyperthermia/reduced body temperature regulation);